GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » Deferred Tax

Zai Lab (HKSE:09688) Deferred Tax : HK$0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Zai Lab's change in deferred tax for the three months ended in Sep. 2024 was HK$0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Sep. 2024 was HK$0 Mil.


Zai Lab Deferred Tax Historical Data

The historical data trend for Zai Lab's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Deferred Tax Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Deferred Tax
Get a 7-Day Free Trial Premium Member Only - - - - -

Zai Lab Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Zai Lab Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zai Lab Deferred Tax Related Terms

Thank you for viewing the detailed overview of Zai Lab's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab Business Description

Traded in Other Exchanges
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Ubs Group Ag 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Janus Henderson Group Plc 2102 Investment manager
Du Ying 2101 Beneficial owner
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Fmr Llc 2201 Interest of corporation controlled by you
Invesco Advisers, Inc. 2102 Investment manager
Invesco Developing Markets Fund 2106 Person having a security interest in shares
Baillie Gifford & Co 2102 Investment manager
Citigroup Inc. 2502 Approved lending agent

Zai Lab Headlines

No Headlines